Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of obesity~* diagnosed ORG by renal biopsy~* LDL\>3.37mmol/L~* Proteinuria 0.5-3.5g/d~* eGFR (CKD-EPI formula) \> 30ml/min~Exclusion Criteria:~* Other concomitant renal diseases~* Endocrine or drug-induced obesity;~* Type 2 diabetes~* eyes or obvious microscopic hematuria;~* Swallowing difficulty / severe gastrointestinal dysfunction~* intestinal obstruction;~* severe arrhythmia;~* Hypophosphatemia (\<0.7mmol/L);~* allergic to Sevelamer Carbonate~* unable to well cooperate~* Females who are in the period of gestation or lactation, or refuse to use contraception;~* participated in other clinical trial of drug within three months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A Group (Type: EXPERIMENTAL): None
- B Group (Type: EXPERIMENTAL): None
- C Group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).